Toggle light / dark theme

Saccharine, aspartame, sucralose.


New research has discovered that common artificial sweeteners can cause previously healthy gut bacteria to become diseased and invade the gut wall, potentially leading to serious health issues.

The study, published in the International Journal of Molecular Sciences, is the first to show the of some of the most widely used artificial sweeteners—saccharin, sucralose, and aspartame—on two types of gut bacteria, E. coli (Escherichia coli) and E. faecalis (Enterococcus faecalis).

Previous studies have shown that artificial sweeteners can change the number and type of bacteria in the gut, but this new molecular research, led by academics from Anglia Ruskin University (ARU), has demonstrated that sweeteners can also make the bacteria pathogenic. It found that these can attach themselves to, invade, and kill Caco-2 cells, which are that line the wall of the intestine.

The U.S. is facing an unprecedented shortage of obstetricians and gynecologists (OB/GYNs). According to the American College of Obstetricians and Gynecologists, around half of the nation’s counties don’t have access to even a single OB/GYN, which means more than 10 million women are in need of OB/GYNs for primary care. Alarmingly, there are now 8000 fewer women’s health specialists than needed, and that number is predicted rise to 22000 by mid-century.


As the nation’s largest group of Maternal-Fetal Medicine (MFM) and OB/GYN Hospitalist providers, Obstetrix Medical Group is uniquely addressing this critical issue. With multiple diverse TeleMFM programs around the country, Obstetrix provides a key solution for hospitals and community OB/GYN physicians that improves access to specialty care for women with high-risk pregnancies.

Mednax clinicians have long relied on the benefits of telehealth to complement traditional in-person care. MFM providers specifically have utilized various forms of telehealth since the late 1980s. Today, virtual care continues to play an essential role in bridging distance gaps and bringing the highest quality care to patients in need, no matter their location. Through the use Vsee, one of Mednax’s primary telehealth platform vendors, as well as others, clinicians across the country are finding a silver lining during the COVID-19 pandemic. Though helpful in any region, in the rural areas of the Mountain West, it has become even more of a blessing. We spoke with Oliver (Bill) Jones, M.D., about how telehealth integrated into their practice and how it has positively impacted their high-risk patients.

A need for change

Obstetrix Medical Group of Colorado has been practicing for over thirty years and provides outreach to Colorado, Wyoming and Nebraska— a geography that requires long travel time for either physicians or patients. Although they have been in practice for a while, using telehealth to care for patients has accelerated in use for most members of their group. Dr. Jones explains that their team flew across states to meet with their patients before the pandemic, making for very long days. In addition, the unpredictable Colorado weather sometimes affected the flight’s departures and return times. Dr. Jones laughs, remembering a particularly nasty snowstorm back in November of 2019 that jumpstarted the conversations about telehealth. The flight to Casper, Wyo., was cancelled but Dr. Jones did not want the patients to have to reschedule appointments. He worked with the sonographer to come up with an alternative solution of virtual visits.

Google has invested heavily in healthcare. I think in the end, they will be the ultimate profile provider for users. Just connect your electronic health record with your personal profile combined with Fitbit wearable technologies.


Google has made moves to expand its presence in the healthcare sector during the last 12 months, including multiple partnerships with health systems, several new product launches and efforts to facilitate the country’s COVID-19 vaccine rollout.

Below is a timeline of Google’s key healthcare moves reported by Becker’s Hospital Review since June 2020.

June 18, 2020: Google sister company Verily developed a program to help employees and students safely return to offices and shared spaces while monitoring for COVID-19. The program, dubbed Healthy at Work, is powered by Verily’s software and COVID-19 testing infrastructure.

According to a new study1, an anti-inflammatory protein called interleukin-38, or IL-38, is decreased in the brains of people with autism.

To help protect the brain from injury and infection, the immune cells in the brain, called microglia, usually produce inflammatory molecules2. But it is a tough balance – an inappropriate, or too large, inflammatory response can harm the health of the brain.

Research has shown that there may be changes in the structure and function of microglia in the brains of people with autism. This suggests that atypical inflammatory responses may play a role in autism3, 4, 5.

Smart strategies like this can help workers learn to embrace technological change. If the government helps people plan their next move if and when they’re no longer needed in their current job, workers will be able to roll with the economy’s punches more easily. Combined with national health insurance, education and retraining assistance — and a robust unemployment insurance system — it could make terror of job loss a thing of the past.


The U.S. government must assuage people’s anxiety about technology upending their working lives, in part by helping them forge new career paths.

Machine learning techniques have contributed to progress in science and technology fields ranging from health care to high-energy physics. Now, machine learning is poised to help accelerate the development of stronger alloys, particularly stainless steels, for America’s thermal power generation fleet. Stronger materials are key to producing energy efficiently, resulting in economic and decarbonization benefits.

“The use of ultra-high-strength steels in power plants dates back to the 1950s and has benefited from gradual improvements in the materials over time,” says Osman Mamun, a postdoctoral research associate at Pacific Northwest National Laboratory (PNNL). “If we can find ways to speed up improvements or create new materials, we could see enhanced efficiency in plants that also reduces the amount of carbon emitted into the atmosphere.”

Mamun is the lead author on two recent, related journal articles that reveal new strategies for machine learning’s application in the design of advanced alloys. The articles chronicle the research outcomes of a joint effort between PNNL and the National Energy Technology Laboratory (NETL). In addition to Mamun, the research team included PNNL’s Arun Sathanur and Ram Devanathan and NETL’s Madison Wenzlick and Jeff Hawk.

Most cases of Parkinson’s disease are considered idiopathic – they lack a clear cause. Yet researchers increasingly believe that one factor is environmental exposure to trichloroethylene (TCE), a chemical compound used in industrial degreasing, dry-cleaning and household products such as some shoe polishes and carpet cleaners.

To date, the clearest evidence around the risk of TCE to human health is derived from workers who are exposed to the chemical in the work-place. A 2008 peer-reviewed study in the Annals of Neurology, for example, found that TCE is “a risk factor for parkinsonism.” And a 2011 study echoed those results, finding “a six-fold increase in the risk of developing Parkinson’s in individuals exposed in the workplace to trichloroethylene (TCE).”

Dr Samuel Goldman of The Parkinson’s Institute in Sunnyvale, California, who co-led the study, which appeared in the Annals of Neurology journal, wrote: “Our study confirms that common environmental contaminants may increase the risk of developing Parkinson’s, which has considerable public health implications.” It was off the back of studies like these that the US Department of Labor issued a guidance on TCE, saying: “The Board recommends […] exposures to carbon disulfide (CS2) and trichloroethylene (TCE) be presumed to cause, contribute, or aggravate Parkinsonism.”

There are now several monoclonal antibodies, identical copies of a therapeutic antibody produced in large numbers, that are authorized for the treatment of COVID-19. But in the ongoing effort to beat this terrible pandemic, there’s plenty of room for continued improvements in treating infections with SARS-CoV-2, the virus that causes COVID-19.

With this in mind, I’m pleased to share progress in the development of a specially engineered therapeutic antibody that could be delivered through a nasal spray. Preclinical studies also suggest it may work even better than existing antibody treatments to fight COVID-19, especially now that new SARS-CoV-2 “variants of concern” have become increasingly prevalent.

These findings come from Zhiqiang An, The University of Texas Health Science Center at Houston, and Pei-Yong Shi, The University of Texas Medical Branch at Galveston, and their colleagues. The NIH-supported team recognized that the monoclonal antibodies currently in use all require time-consuming, intravenous infusion at high doses, which has limited their use. Furthermore, because they are delivered through the bloodstream, they aren’t able to reach directly the primary sites of viral infection in the nasal passages and lungs. With the emergence of new SARS-CoV-2 variants, there’s also growing evidence that some of those therapeutic antibodies are becoming less effective in targeting the virus.-Dr Francis Collins.

The plasticizers contained in many everyday objects can impair important brain functions in humans. Biologists from the University of Bayreuth warn of this danger in an article in Communications Biology. Their study shows that even small amounts of the plasticizers bisphenol A and bisphenol S disrupt the transmission of signals between nerve cells in the brains of fish. The researchers consider it very likely that similar interference can also occur in the brains of adult humans. They, therefore, call for the rapid development of alternative plasticizers that do not pose a risk to the central nervous system.

Bisphenols are plasticizers that are found in a large number of plastic products worldwide — for example, in food packaging, plastic tableware, drinking bottles, toys, tooth fillings, and babies’ dummies. In recent years, numerous health risks have already been associated with them, especially with bisphenol A (BPA). The Bayreuth research team led by Dr. Peter Machnik at the Animal Physiology research group (led by Prof. Dr. Stefan Schuster) has now for the first time investigated the effects of plasticizers on signal transmission between nerve cells in the adult brain. The study covers not only BPA, but also bisphenol S (BPS), which is often considered less harmful to health. Their findings: Both plasticizers impair communication between the nerve cells of the brain.

Perhaps better than medication.


Summary: Inexpensive, commercial video games may help those suffering from anxiety and depression to combat their symptoms. Researchers found that, in addition to conventional games, virtual reality games could help people overcome mental health problems.

Source: Lero

Popular video games have the potential to provide low-cost, easy access, effective and stigma-free support for some mental health issues, researchers at Lero, the Science Foundation Ireland Research Centre for Software, have found.

The team at Lero, a world leader in connected-health research, said video games could be used where conventional therapies are not available because of cost or location, or as an addition to traditional therapeutic treatments for depression or anxiety.